Search results for " tolerance"

showing 10 items of 760 documents

The anti-oxidant capacity of tumour glycolysis.

2009

In this mini-review data are summarised which provide evidence for the biological and clinical significance of tumour glycolysis and of its relationship to the redox state of cancer cells.Malignant transformation is associated with an overexpression of numerous glycolysis-related genes in the vast majority of human cancers. At the same time, glycolytic activity and glycolysis-linked metabolic milieu are often variable between individual tumours which induces large variations in treatment response and aggressiveness. Currently, there is no genetic or proteomic marker for the prediction of the therapeutic response for individual tumours, but the prognostic value of tumour lactate accumulation…

BiologyModels BiologicalRadiation ToleranceAntioxidantsMetastasisRadioresistanceNeoplasmsmedicineBioluminescence imagingAnimalsHumansRadiology Nuclear Medicine and imagingClinical significanceGlycolysisLactic AcidHypoxiaGenechemistry.chemical_classificationReactive oxygen speciesRadiological and Ultrasound TechnologyCancermedicine.diseaseBiochemistrychemistryLuminescent MeasurementsCancer researchGlycolysisDNA DamageInternational journal of radiation biology
researchProduct

Evaluation of B-cell secretion and peripheral insulin resistance during pregnancy and after delivery in gestational diabetes mellitus with obesity

1988

Nine pregnant women with gestational diabetes mellitus (GDM) were studied. Six normal pregnant women and six normal nonpregnant women were evaluated as control groups. All the women underwent oral glucose tolerance test and glucose clamp during the third trimester of pregnancy and two months after delivery. During OGTT, glucose, C-peptide and insulin plasma levels were determined. C-peptide and insulin values in the late phase of OGTT were higher during pregnancy than after delivery in both groups. In gestational diabetic women, the M-value in the second steady-state during glucose clamp was lower than in controls, both during pregnancy and after delivery. Nevertheless, in both groups the M…

Blood GlucoseAdultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPregnancy in DiabeticsObesity; Glucose Tolerance Test; Reference Values; Humans; Diabetes Mellitus; Islets of Langerhans; Insulin; Blood Glucose; Pregnancy; Puerperal Disorders; Adult; Insulin Resistance; Female; Pregnancy in DiabeticsIslets of LangerhansEndocrinologyInsulin resistanceReference ValuesPregnancyDiabetes mellitusInternal medicineInternal MedicinemedicineDiabetes MellitusHumansInsulinObesityPregnancyGlucose tolerance testSettore MED/12 - Gastroenterologiamedicine.diagnostic_testbusiness.industryInsulinGeneral MedicinePuerperal DisordersGlucose clamp techniqueGlucose Tolerance Testmedicine.diseaseGestational diabetesEndocrinologyGestationFemaleInsulin Resistancebusiness
researchProduct

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy

2022

Cushing’s disease (CD) causes diabetes mellitus (DM) through different mechanisms in a significant proportion of patients. Glucose metabolism has rarely been assessed with appropriate testing in CD; we aimed to evaluate hormonal response to a mixed meal tolerance test (MMTT) in CD patients and analyzed the effect of pasireotide (PAS) on glucose homeostasis. To assess gastro-entero-pancreatic hormones response in diabetic (DM+) and non-diabetic (DM–) patients, 26 patients with CD underwent an MMTT. Ten patients were submitted to a second MMTT after two months of PAS 600 µg twice daily. The DM+ group had significantly higher BMI, waist circumference, glycemia, HbA1c, ACTH le…

Blood GlucoseCushing’s disease; diabetes mellitus; incretin; mixed meal test tolerance test; pasireotidemixed meal test tolerance testGastric Inhibitory PolypeptideIncretinsCatalysisInorganic ChemistryGlucagon-Like Peptide 1HumansInsulinPhysical and Theoretical ChemistryPituitary ACTH HypersecretionMolecular BiologyMealsSpectroscopyGlycated HemoglobinpasireotideC-Peptidediabetes mellituOrganic Chemistrydigestive oral and skin physiologyGeneral MedicineCushing’s diseaseGlucagonincretinComputer Science ApplicationsDiabetes Mellitus Type 2Cushing’s disease; mixed meal test tolerance test; diabetes mellitus; incretin; pasireotidediabetes mellituspasireotide.Insulin ResistanceSomatostatinhormones hormone substitutes and hormone antagonists
researchProduct

Glucose regulation and physical performance among older people: the Helsinki Birth Cohort Study

2018

Aims To assess whether disturbances in glucose regulation are associated with impairment in physical performance during a 10-year follow-up. Methods 475 Men and 603 women from the Helsinki Birth Cohort Study were studied. Glucose regulation was evaluated with a 2-h 75-g oral glucose tolerance test (OGTT) in 2001-2004. Subjects were categorised as having either impaired fasting glucose (IFG), impaired glucose tolerance (IGT), newly diagnosed diabetes or previously known diabetes. Physical performance was assessed approximately 10 years later using the validated senior fitness test (SFT). The relationship between glucose regulation and the overall SFT score was estimated using multiple linear…

Blood GlucoseMaleAgingFITNESSEpidemiologyEndocrinology Diabetes and MetabolismPhysical fitnessCohort StudiesImpaired glucose toleranceMUSCLE STRENGTHDiabetes mellitus0302 clinical medicineEndocrinologyglukoosi-intoleranssiEpidemiology030212 general & internal medicineepidemiologiaFinlandAged 80 and overeducation.field_of_studyGlucose tolerance testdiabetesmedicine.diagnostic_testINDEPENDENCEGeneral Medicinefyysinen kuntodiabetes mellitusOriginal ArticleFemaleHEALTHmedicine.medical_specialtyBODY-COMPOSITIONPopulation030209 endocrinology & metabolismglucose tolerance testIMPAIRMENTSPrediabetic State03 medical and health sciencesUS ADULTSInternal medicineDiabetes mellitusGlucose IntoleranceInternal MedicinemedicineHumanseducationAgedbusiness.industryDISABILITYPhysical fitnessGlucose Tolerance Testmedicine.diseaseImpaired fasting glucoseHIGH-RISKAgeingikääntyminenverensokeri3121 General medicine internal medicine and other clinical medicineBlood sugar regulation3111 BiomedicinebusinessMEXICAN-AMERICANSFollow-Up StudiesActa Diabetologica
researchProduct

Glucose regulation and grip strength in adults: Findings from the Helsinki Birth Cohort Study.

2021

Aim: this study aimed to assess the association between grip strength and glucose regulation in a cross-sectional setting.Methods: using data from the Helsinki Birth Cohort Study, 924 men and 953 women were studied at a mean age of 61.6 years. Grip strength was assessed in the dominant hand using a Newtest Grip Force dynamometer. A standard 2-h 75 g oral glucose tolerance test (OGTT) was used to define glucose regulation. The participants were classified into four groups: normoglycaemia, prediabetes (impaired fasting glucose or impaired glucose tolerance), newly diagnosed diabetes and previously known diabetes. The association between grip strength and glucose regulation was assessed using …

Blood GlucoseMaleAgingHealth (social science)EpidemiologyPhysical fitnesspuristusvoimaprediabetesImpaired glucose toleranceCohort StudiesMUSCLE STRENGTHGrip strengthDiabetes mellitus0302 clinical medicine030212 general & internal medicinePrediabetesepidemiologiakohorttitutkimusRISK2. Zero hungerdiabetesHand Strength3. Good healthfyysinen kuntodiabetes mellitusepidemiologyFemaleHEALTHmedicine.medical_specialtyPrediabetic State03 medical and health sciencesAGEDiabetes mellitusInternal medicinemedicineHumansOLDER-ADULTS030214 geriatricsbusiness.industryDIABETES-MELLITUSPhysical fitnessmedicine.diseaseImpaired fasting glucoseikääntyminenPHYSICAL-ACTIVITYCross-Sectional StudiesGlucoseDiabetes Mellitus Type 2Grip strengthMOBILITYgrip strength3121 General medicine internal medicine and other clinical medicinephysical fitnessBlood sugar regulationGeriatrics and GerontologybusinessPrediabetesGerontologyBody mass indexArchives of gerontology and geriatrics
researchProduct

Persistence of the effect of birth size on dysglycaemia and type 2 diabetes in old age: AGES-Reykjavik Study

2012

We studied the effect of birth size on glucose and insulin metabolism among old non-diabetic individuals. We also explored the combined effect of birth size and midlife body mass index (BMI) on type 2 diabetes in old age. Our study comprised 1,682 Icelanders whose birth records included anthropometrical data. The same individuals had participated in the prospective population-based Reykjavik Study, where BMI was assessed at a mean age of 47 years, and in the AGES-Reykjavik Study during 2002 to 2006, where fasting glucose, insulin and HbA₁c were measured and homeostasis model assessment for the degree of insulin resistance (HOMA-IR) calculated at a mean age of 75.5 years. Type 2 diabetes was…

Blood GlucoseMaleAgingmedicine.medical_specialtyPediatricsBirth weightPopulationIcelandType 2 diabetesWeight GainArticleBody Mass IndexInsulin resistanceDiabetes mellitusInternal medicinemedicineBirth WeightHumansInsulinsyntymäpainoProspective StudieseducationAgedAged 80 and overGlucose tolerance testeducation.field_of_studydiabetesmedicine.diagnostic_testbusiness.industryIncidenceagingGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseLow birth weightikääntyminenEndocrinologyDiabetes Mellitus Type 2Population SurveillanceDisease ProgressionFemaleInsulin ResistanceGeriatrics and Gerontologymedicine.symptombusinessBody mass indexbirth sizeFollow-Up StudiesAGE
researchProduct

Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endotheli…

2015

Endothelial dysfunction plays a key role in obesity-induced risk of cardiovascular disease. The aim of the present study was to analyze the effect of chronic peroxisome proliferator-activated receptor (PPAR)β/δ agonist GW0742 treatment on endothelial function in obese mice fed a high-fat diet (HFD).Five-week-old male mice were allocated to one of the following groups: control, control-treated (GW0742, 3 mg/kg per day, by oral gavage), HFD, HFD + GW0742, HFD + GSK0660 (1 mg/kg/day, intraperitoneal) or HFD-GW0742-GSK0660 and followed for 11 or 13 weeks. GW0742 administration to mice fed HFD prevented the gain of body weight, heart and kidney hypertrophy, and fat accumulation. The increase in …

Blood GlucoseMaleAgonistmedicine.medical_specialtyNitric Oxide Synthase Type IIIEndotheliumPhysiologymedicine.drug_classCaveolin 1Peroxisome proliferator-activated receptorThiophenesDiet High-FatGW0742MiceInsulin resistanceInternal medicineInternal MedicinemedicineAnimalsObesityPPAR deltaSulfonesEndothelial dysfunctionReceptorPPAR-betaAortachemistry.chemical_classificationInterleukin-6Tumor Necrosis Factor-alphabusiness.industryGlucose Tolerance TestPeroxisomemedicine.diseaseToll-Like Receptor 4VasodilationThiazolesEndocrinologymedicine.anatomical_structureAdipose TissuechemistryHypertensionAdiponectinEndothelium VascularInsulin ResistanceReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessJournal of Hypertension
researchProduct

Insulin resistance and endogenous digoxin-like factor in obese hypertensive patients with glucose intolerance

1992

Hypertensive obese subjects with glucose intolerance have hyperinsulinaemia, insulin resistance and intracellular cation imbalance resulting in increased sodium content. The aim of our study was to assess in these patients plasma levels of endogenous digoxin-like factor (EDLF), an inhibitor of the sodium-pump mechanism. We studied 14 hypertensive and 12 normotensive subjects with obesity and glucose intolerance for fasting blood glucose, and plasma insulin, C-peptide and EDLF levels: the two groups were matched for age and BMI and were studied after a 2-week wash-out period from hypotensive drugs. Compared with normotensives, hypertensive subjects had higher plasma insulin levels, a greater…

Blood GlucoseMaleDigoxinmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndogenyEndogenous digoxin-like factorEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInternal MedicineHumansInsulinMedicineObesityImmunoreactive insulinC-Peptidebusiness.industryInsulinBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle AgedSaponinsmedicine.diseaseObesityCardenolidesEndocrinologyHyperglycemiaHypertensionFemaleInsulin ResistanceSodium-Potassium-Exchanging ATPasebusinessIntracellularActa Diabetologica
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Microregional distributions of glucose, lactate, ATP and tissue pH in experimental tumours upon local hyperthermia and/or hyperglycaemia

1993

Microregional distributions of glucose, lactate and ATP concentrations as well as tissue pH values were determined in subcutaneous rat tumours during normothermia and normoglycaemia, and upon local hyperthermia (HT) and/or hyperglycaemia (HG). Experiments were performed in order to investigate whether, and to what extent, these adjuvant therapeutic measures applied alone or in combination can modify the bioenergetic and metabolic status, parameters that are known to markedly influence the therapeutic response of tumours to heat. Local HT was performed in a saline bath (44 degrees C/2 h) and HG was induced by i.v. infusion of glucose for 2.5 h (blood glucose levels during heating: 35-40 mM).…

Blood GlucoseMaleHyperthermiaCancer Researchmedicine.medical_specialtyBioenergeticsmedicine.medical_treatmentBiologyRats Sprague-DawleyAdenosine TriphosphateInternal medicinemedicineAnimalsLactic AcidSalineAcidosisGlucose tolerance testmedicine.diagnostic_testHyperthermia InducedGeneral MedicineMetabolismHydrogen-Ion Concentrationmedicine.diseaseRatsGlucoseEndocrinologyOncologyMechanism of actionHyperglycemiaLactatesCrabtree effectSarcoma Experimentalmedicine.symptomJournal of Cancer Research and Clinical Oncology
researchProduct